Abstract
Introduction: Although safety data demonstrated the efficacy and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination for all individuals over 6 months of age, including pregnant and breastfeeding individuals, optimal treatment courses for symptomatic pregnant and lactating individuals infected with SARS-CoV-2 remain to be defined. Case Description: A coronavirus disease 2019 (COVID-19)-vaccinated breastfeeding woman received anti-SARS-CoV-2 monoclonal antibody treatment casirivimab–imdevimab 5 days after diagnosis of a symptomatic breakthrough SARS-CoV-2 infection. Results and Conclusions: The patient did not present with obvious defects in innate or adaptive cellular subsets, but compared with controls had minimal maternal antibody response to recommended pregnancy vaccinations including SARS-CoV-2 and tetanus, diphtheria, pertussis (TDaP). The outcome of the monoclonal antibody infusion treatment was favorable as it transiently increased SARS-CoV-2 antibody titers in plasma and human milk compartments.
Document Type
Article
Publication Date
2023
Digital Object Identifier (DOI)
https://doi.org/10.1089/bfm.2023.0102
Funding Information
This research was supported by grants from the National Institutes of Health R01AI145910 (I.M.) and R01AI142841 (I.M.). The funding source had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Repository Citation
Marshall, Nicole E.; Blanton, Madison B.; Doratt, Brianna M.; Malherbe, Delphine C.; Rincon, Monica; and Messaoudi, Ilhem, "Monoclonal Antibody Therapy of Breastfeeding Patient Infected with SARS-CoV-2: A Case Report" (2023). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 176.
https://uknowledge.uky.edu/microbio_facpub/176
Notes/Citation Information
© Mary Ann Liebert, Inc.